Exact Mass: 511.1181274

Exact Mass Matches: 511.1181274

Found 57 metabolites which its exact mass value is equals to given mass value 511.1181274, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

3-Methyl-1-hydroxybutyl-ThPP

3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-{[hydroxy(phosphonooxy)phosphoryl]oxy}ethyl)-2-(1-hydroxy-3-methylbutyl)-4-methyl-1,3-thiazol-3-ium

C17H29N4O8P2S+ (511.1181274)

3-Methyl-1-hydroxybutyl-ThPP is an intermediate in valine, leucine and isoleucine degradation(KEGG ID C15974). It is the second to last step in the synthesis of 3-methylbutanoyl-CoA and is converted from 4-methyl-2-oxopentanoate via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]. It is then converted to S-(3-methylbutanoyl)-dihydrolipoamide-E via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]. [HMDB] 3-Methyl-1-hydroxybutyl-ThPP is an intermediate in valine, leucine and isoleucine degradation(KEGG ID C15974). It is the second to last step in the synthesis of 3-methylbutanoyl-CoA and is converted from 4-methyl-2-oxopentanoate via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]. It is then converted to S-(3-methylbutanoyl)-dihydrolipoamide-E via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4].

2-Methyl-1-hydroxybutyl-ThPP

3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-{[hydroxy(phosphonooxy)phosphoryl]oxy}ethyl)-2-[(2S)-1-hydroxy-2-methylbutyl]-4-methyl-1,3-thiazol-3-ium

C17H29N4O8P2S+ (511.1181274)

2-Methyl-1-hydroxybutyl-ThPP is an intermediate in Valine, leucine and isoleucine degradation. 2-Methyl-1-hydroxybutyl-ThPP is the second to last step for the synthesis of (S)-2-Methylbutanoyl-CoA. 2-Methyl-1-hydroxybutyl-ThPP is converted from (S)-3-Methyl-2-oxopentanoic acid via the enzyme 2-oxoisovalerate dehydrogenase E1 component, alpha subunit(EC 1.2.4.4). It is then converted to S-(2-Methylbutanoyl)-dihydrolipoamide-E via the same enzyme. 2-Methyl-1-hydroxybutyl-ThPP is an intermediate in Valine, leucine and isoleucine degradation. 2-Methyl-1-hydroxybutyl-ThPP is the second to last step for the synthesis of (S)-2-Methylbutanoyl-CoA. 2-Methyl-1-hydroxybutyl-ThPP is converted

trans-zeatin riboside diphosphate

9-ribosyl-trans-zeatin 5-diphosphate

C15H23N5O11P2 (511.08692679999996)

A purine ribonucleoside 5-diphosphate that is ADP substituted at position N-6 by a (2E)-4-hydroxy-3-methylbut-2-en-1-yl group.

Uzel (TN)

Leucovorin calcium (USP)

C20H21N7O7. Ca (511.11283060000005)

V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AF - Detoxifying agents for antineoplastic treatment D020011 - Protective Agents > D000931 - Antidotes C2140 - Adjuvant > C2078 - Folic Acid Derivative D018977 - Micronutrients > D014815 - Vitamins Therapeutic category: 3929 Levoleucovorin Calcium (Calcium levofolinate), a levo isoform of Leucovorin Calcium (HY-13664), possesses antineoplastic effects. Levoleucovorin Calcium is also an augmentor of 5-fluorouracil (HY-90006) cytotoxicity against cancer[1][2].

Cefetamet pivoxyl

{7-[2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carbonyloxy}methyl 2,2-dimethylpropanoate

C20H25N5O7S2 (511.119534)

4-[2-[(1R)-1-(N-(4-Chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid

4-[2-[(1R)-1-(N-(4-Chlorophenyl)sulphonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid

C24H21ClF3NO4S (511.0831852000001)

(+)-Indocarbazostatin

C28H21N3O7 (511.1379436)

DTXSID90996509

C20H25N5O11 (511.15504999999996)

Cys Cys Thr Trp

(2S)-2-[(2S,3R)-2-[(2R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-hydroxybutanamido]-3-(1H-indol-3-yl)propanoic acid

C21H29N5O6S2 (511.1559174)

Cys Cys Trp Thr

(2S,3R)-2-[(2S)-2-[(2R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxybutanoic acid

C21H29N5O6S2 (511.1559174)

Cys Met Met Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-(methylsulfanyl)butanamido]-4-(methylsulfanyl)butanamido]-4-carbamoylbutanoic acid

C18H33N5O6S3 (511.1592878)

Cys Met Gln Met

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-(methylsulfanyl)butanamido]-4-carbamoylbutanamido]-4-(methylsulfanyl)butanoic acid

C18H33N5O6S3 (511.1592878)

Cys Gln Met Met

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-carbamoylbutanamido]-4-(methylsulfanyl)butanamido]-4-(methylsulfanyl)butanoic acid

C18H33N5O6S3 (511.1592878)

Cys Thr Cys Trp

(2S)-2-[(2R)-2-[(2S,3R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxybutanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C21H29N5O6S2 (511.1559174)

Cys Thr Trp Cys

(2R)-2-[(2S)-2-[(2S,3R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxybutanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanoic acid

C21H29N5O6S2 (511.1559174)

Cys Trp Cys Thr

(2S,3R)-2-[(2R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-3-hydroxybutanoic acid

C21H29N5O6S2 (511.1559174)

Cys Trp Thr Cys

(2R)-2-[(2S,3R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxybutanamido]-3-sulfanylpropanoic acid

C21H29N5O6S2 (511.1559174)

Met Cys Met Gln

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-sulfanylpropanamido]-4-(methylsulfanyl)butanamido]-4-carbamoylbutanoic acid

C18H33N5O6S3 (511.1592878)

Met Cys Gln Met

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-sulfanylpropanamido]-4-carbamoylbutanamido]-4-(methylsulfanyl)butanoic acid

C18H33N5O6S3 (511.1592878)

Met Met Cys Gln

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-4-(methylsulfanyl)butanamido]-3-sulfanylpropanamido]-4-carbamoylbutanoic acid

C18H33N5O6S3 (511.1592878)

Met Met Gln Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-4-(methylsulfanyl)butanamido]-4-carbamoylbutanamido]-3-sulfanylpropanoic acid

C18H33N5O6S3 (511.1592878)

Met Gln Cys Met

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-4-carbamoylbutanamido]-3-sulfanylpropanamido]-4-(methylsulfanyl)butanoic acid

C18H33N5O6S3 (511.1592878)

Met Gln Met Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-4-carbamoylbutanamido]-4-(methylsulfanyl)butanamido]-3-sulfanylpropanoic acid

C18H33N5O6S3 (511.1592878)

Gln Cys Met Met

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-sulfanylpropanamido]-4-(methylsulfanyl)butanamido]-4-(methylsulfanyl)butanoic acid

C18H33N5O6S3 (511.1592878)

Gln Met Cys Met

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-(methylsulfanyl)butanamido]-3-sulfanylpropanamido]-4-(methylsulfanyl)butanoic acid

C18H33N5O6S3 (511.1592878)

Gln Met Met Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-(methylsulfanyl)butanamido]-4-(methylsulfanyl)butanamido]-3-sulfanylpropanoic acid

C18H33N5O6S3 (511.1592878)

Thr Cys Cys Trp

(2S)-2-[(2R)-2-[(2R)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C21H29N5O6S2 (511.1559174)

Thr Cys Trp Cys

(2R)-2-[(2S)-2-[(2R)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanoic acid

C21H29N5O6S2 (511.1559174)

Thr Trp Cys Cys

(2R)-2-[(2R)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-3-sulfanylpropanoic acid

C21H29N5O6S2 (511.1559174)

Trp Cys Cys Thr

(2S,3R)-2-[(2R)-2-[(2R)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-hydroxybutanoic acid

C21H29N5O6S2 (511.1559174)

Trp Cys Thr Cys

(2R)-2-[(2S,3R)-2-[(2R)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-3-hydroxybutanamido]-3-sulfanylpropanoic acid

C21H29N5O6S2 (511.1559174)

Trp Thr Cys Cys

(2R)-2-[(2R)-2-[(2S,3R)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-hydroxybutanamido]-3-sulfanylpropanamido]-3-sulfanylpropanoic acid

C21H29N5O6S2 (511.1559174)

Citicoline sodium salt

C14H26N4NaO11P2 (511.09709659999993)

TG 100572 (Hydrochloride)

C26H27Cl2N5O2 (511.1541702)

sodium 3-[[4-(benzoylethylamino)-2-methylphenyl]azo]-4-hydroxynaphthalene-1-sulphonate

C26H22N3NaO5S (511.1177802000001)

Tetrodotoxin citrate

C17H25N3O15 (511.128562)

Arzoxifene hydrochloride

C28H30ClNO4S (511.1583970000001)

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent

Leucovorin Calcium

Folinic acid (Calcium)

C20H21CaN7O7 (511.1128306)

V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AF - Detoxifying agents for antineoplastic treatment D020011 - Protective Agents > D000931 - Antidotes C2140 - Adjuvant > C2078 - Folic Acid Derivative D018977 - Micronutrients > D014815 - Vitamins Levoleucovorin Calcium (Calcium levofolinate), a levo isoform of Leucovorin Calcium (HY-13664), possesses antineoplastic effects. Levoleucovorin Calcium is also an augmentor of 5-fluorouracil (HY-90006) cytotoxicity against cancer[1][2].

BMS 299897

4-[2-[(1R)-1-(N-(4-Chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid

C24H21ClF3NO4S (511.0831852000001)

[6-acetyloxy-5-(2,5-dioxopyrrol-1-yl)-3-oxospiro[2-benzofuran-1,9-xanthene]-3-yl] acetate

C28H17NO9 (511.09032720000005)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

(2-Amino-2-biphenylyl)(chloro)palladium - tris(2-methyl-2-propanyl)phosphine (1:1)

C24H37ClNPPd (511.1386752000001)

(E)-CefetametPivoxil

C20H25N5O7S2 (511.119534)

[3,4-dihydroxy-5-[6-[[(E)-4-hydroxy-3-methylbut-2-enyl]amino]purin-9-yl]oxolan-2-yl]methyl phosphono hydrogen phosphate

C15H23N5O11P2 (511.08692679999996)

2-[(3-cyano-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-2-yl)thio]-N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]acetamide

C24H25N5O4S2 (511.134789)

2,4-Dichloro-benzoic acid 2-{[4-(2,2-dimethyl-propionylamino)-benzoyl]-hydrazonomethyl}-phenyl ester

C26H23Cl2N3O4 (511.10655380000003)

N-[3-[[[3-[(5-bromo-2-pyridinyl)-[(4-chlorophenyl)methyl]amino]propylamino]-sulfanylidenemethyl]amino]propyl]acetamide

C21H27BrClN5OS (511.0808102000001)

N-[[(4S,5R)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide

C21H26BrN3O5S (511.0776446000001)

alpha-Kdo1Me-(2->8)-alpha-Kdo-OAll(1-)

C20H31O15- (511.16628760000003)

3-Methyl-1-hydroxybutyl-TPP

3-Methyl-1-hydroxybutyl-ThPP

C17H29N4O8P2S+ (511.1181274)

2-Methyl-1-hydroxybutyl-TPP

2-Methyl-1-hydroxybutyl-ThPP

C17H29N4O8P2S+ (511.1181274)

ST 21:6;O7;Tau

C23H29NO10S (511.1512094000001)

CVT-11127

C25H23Cl2N5O3 (511.1177868)

CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer[1]. CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer[1].

PPTN (hydrochloride)

C29H25ClF3NO2 (511.1525816)

PPTN hydrochloride is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and anti-immune activity[1].